Semaglutide vs Tirzepatide: How the Two Leading GLP-1 Drugs Compare

Semaglutide and tirzepatide are the two most prescribed injectable medications in the GLP-1 era, and most "which should I take" decisions come down to a choice between them. They are often discussed as if they were interchangeable, but they are different molecules with different mechanisms — and one head-to-head trial actually pitted them against each other. This comparison covers what separates them, what the evidence shows, and how to think about the trade-offs.

Quick Reference: Semaglutide vs Tirzepatide

• Semaglutide is a single agonist (GLP-1 only). Tirzepatide is a dual agonist (GLP-1 + GIP).
• Brands: semaglutide = Ozempic, Wegovy, Rybelsus; tirzepatide = Mounjaro, Zepbound.
• In the head-to-head SURPASS-2 trial, tirzepatide beat semaglutide 1 mg on both A1C and weight.
• Obesity trials: ~22.5% weight loss for tirzepatide (SURMOUNT-1) vs ~14.9% for semaglutide (STEP 1).
• Semaglutide has the deeper cardiovascular outcomes record (SUSTAIN-6, SELECT); tirzepatide's dedicated CV trial is still running.

Comparison Table

How the Mechanisms Differ

The core distinction is how many hormone pathways each drug activates.

Semaglutide activates the GLP-1 receptor only. GLP-1 (glucagon-like peptide-1) is an incretin hormone your gut releases after eating. Sustained activation suppresses appetite through the hypothalamus, slows gastric emptying so you feel full longer, increases glucose-dependent insulin secretion, and reduces the liver's glucose output. Semaglutide proved that potent, week-long GLP-1 activation alone is enough to drive clinically meaningful weight loss — something earlier, weaker GLP-1 drugs achieved only modestly.

Tirzepatide activates the GLP-1 receptor and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, and it does things GLP-1 doesn't: it enhances insulin sensitivity in peripheral tissues like muscle and fat, influences how fat is stored and metabolized, and appears to complement GLP-1's appetite effects. Notably, tirzepatide's molecular backbone is based on the GIP peptide and it binds GIP receptors with roughly five-fold higher affinity than GLP-1 receptors — so calling it "a GLP-1 drug" undersells the GIP contribution.

The practical result of adding that second receptor is a jump from roughly 15% to roughly 22% average body-weight loss. That's not a marginal gain — it's a different tier of efficacy, and it's the main reason tirzepatide is often described as the more potent option.

Clinical Trial Results

The SURPASS-2 Head-to-Head

This is the trial that matters most, because it compared the two drugs directly. Published in The New England Journal of Medicine in 2021, SURPASS-2 enrolled 1,879 adults with type 2 diabetes on metformin and ran for 40 weeks.

A1C reductions:

• Tirzepatide 5 mg: -2.01%
• Tirzepatide 10 mg: -2.24%
• Tirzepatide 15 mg: -2.30%
• Semaglutide 1 mg: -1.86%

All tirzepatide doses were non-inferior; the 10 mg and 15 mg doses were statistically superior.

Weight loss:

• Tirzepatide 5 mg: -7.6 kg
• Tirzepatide 10 mg: -9.3 kg
• Tirzepatide 15 mg: -12.4 kg
• Semaglutide 1 mg: -6.2 kg

One honest caveat: the comparator was semaglutide 1 mg, the highest Ozempic dose available when the trial was designed. Semaglutide's 2 mg and (for obesity) 2.4 mg doses came later and produce somewhat more weight loss than 1 mg, so the real-world gap at maximum doses is likely narrower than SURPASS-2 implies — though the dose-response curves still favor tirzepatide.

Obesity Programs (STEP vs SURMOUNT)

For weight management specifically, each drug has its own dedicated trial program:

• Semaglutide — STEP 1 (N=1,961, non-diabetic, 68 weeks): -14.9% body weight vs -2.4% placebo; about a third of participants lost more than 20%.
• Tirzepatide — SURMOUNT-1 (N=2,539, non-diabetic, 72 weeks): -16.0% at 5 mg, -21.4% at 10 mg, -22.5% at 15 mg; 63% of the 15 mg group lost more than 20%.

The pattern is consistent across diabetes and obesity populations: tirzepatide produces more weight loss on average.

Cardiovascular Evidence

This is where semaglutide currently leads. The SUSTAIN-6 trial showed a 26% reduction in major adverse cardiovascular events in adults with type 2 diabetes, and the larger SELECT trial extended a 20% reduction to people with obesity without diabetes. Tirzepatide's dedicated cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing, so it doesn't yet have the same level of hard-outcome evidence. For a patient whose main concern is cardiovascular risk reduction, that track record is a real point in semaglutide's favor.

Dosing Comparison

Both use slow titration to limit GI side effects, but the ladders differ.

Semaglutide (injectable):

1. 0.25 mg weekly × 4 weeks (initiation, not therapeutic)
2. 0.5 mg → 1 mg → 2 mg (Ozempic ceiling)
3. For weight management (Wegovy): up to 1.7 mg → 2.4 mg

Tirzepatide:

1. 2.5 mg weekly × 4 weeks (initiation)
2. 5 → 7.5 → 10 → 12.5 → 15 mg, at least 4 weeks per step

Tirzepatide has more granular dose steps, which gives prescribers room to park at an intermediate dose (say 7.5 or 10 mg) if side effects are an issue, without jumping straight to the maximum. Semaglutide is also available as a daily oral tablet (Rybelsus) — the only oral option of the two — though it's less potent than the injectable for weight loss; see our Rybelsus vs Ozempic comparison.

Both injectables use once-weekly subcutaneous administration in the abdomen, thigh, or upper arm, and neither requires reconstitution.

Side Effects Comparison

The GI side-effect profiles overlap heavily, which is expected since both activate GLP-1 receptors.

• Nausea: the most common symptom for both, typically peaking during titration and easing after 4–8 weeks at a stable dose.
• Diarrhea: tended to run slightly higher with tirzepatide in head-to-head data, possibly related to GIP's effects on intestinal motility.
• Vomiting and constipation: broadly comparable.
• Decreased appetite: common with both and, in effect, the intended pharmacology.

Both carry boxed warnings for medullary thyroid carcinoma risk based on rodent studies, and both are contraindicated in people with a personal or family history of MTC or MEN2. Neither should be combined with another GLP-1 receptor agonist. On long-term safety, semaglutide has more years of post-market data simply because it was approved first — a consideration that matters to some patients even though tirzepatide's record so far is reassuring.

Cost, Brands, and Compounding

Because each molecule is sold under multiple brand names, "which is cheaper" depends on the specific product and your coverage:

• Semaglutide: Ozempic (diabetes), Wegovy (weight management), Rybelsus (oral, diabetes).
• Tirzepatide: Mounjaro (diabetes), Zepbound (weight management).

Brand list prices are broadly similar — roughly $1,000–1,350/month without insurance — but out-of-pocket cost is driven by your plan's formulary placement and the manufacturer savings programs, not the sticker price. During the 2022–2024 shortages, compounded versions of both drugs proliferated; as the branded supply normalized, the FDA wound down the shortage designations and the legal space for compounding narrowed considerably. If you're weighing a compounded product, treat its sourcing and concentration as the first questions to verify — we cover the specifics in our tirzepatide guide and semaglutide guide.

Switching Between Them

Switching is common and requires no washout period, but there's an important detail: there is no exact dose equivalence between semaglutide and tirzepatide. They're different molecules. A prescriber moving you from semaglutide to tirzepatide will generally restart you at tirzepatide's lowest dose (2.5 mg) and titrate up, rather than trying to match your old dose milligram-for-milligram.

That restart is exactly when tracking pays off. Your body is adjusting to a new receptor-activation profile, side-effect patterns may shift, and your weight trajectory can change. A continuous log of dose, symptoms, and weight across the switch gives your clinician real data to guide the new titration instead of relying on recall.

Practical Tracking Considerations

Whichever you take, the same data is worth keeping:

• Injection log: date, time, dose, and site (rotate abdomen / thigh / upper arm).
• GI symptoms: severity and timing, especially at each dose increase.
• Weight: weekly, same conditions (morning, fasted, same scale).
• Blood sugar / A1C: if you're managing diabetes.
• Missed doses: and how you handled them.

Because both drugs titrate over months, a clean dose history is genuinely useful at prescriber visits — it's the difference between "I think I've been on the higher dose for a while" and showing the exact ladder you climbed and how you tolerated each step.

Which Is Right for You

Tirzepatide may be preferred when:

• Maximum weight loss is the primary goal (higher average efficacy).
• You want flexible maintenance dosing (5/10/15 mg).
• You've plateaued on semaglutide and want a different mechanism.

Semaglutide may be preferred when:

• Cardiovascular risk reduction is a priority (deeper outcomes data).
• You want the longest post-market safety track record in the class.
• You'd benefit from an oral option (Rybelsus).
• Your insurance covers a semaglutide brand and you're tolerating it well.

Neither is appropriate if:

• You have a personal or family history of medullary thyroid carcinoma or MEN2.
• You have a history of pancreatitis (discuss with your prescriber).
• You are pregnant, planning pregnancy, or breastfeeding.

There's no universal winner here. Tirzepatide is the more potent drug on weight and blood sugar; semaglutide has the longer cardiovascular and safety record and an oral option. The right answer is the one that fits your goal, your tolerance, and what you can actually access and afford — a conversation to have with your prescriber, ideally with your tracked data in hand.

Curious where this class is heading next? The triple agonist retatrutide adds a third receptor on top of tirzepatide's two — see our semaglutide vs tirzepatide vs retatrutide comparison. For the brand-level views, see Ozempic vs Mounjaro (diabetes) and Wegovy vs Zepbound (weight loss).

Frequently Asked Questions

Is tirzepatide better than semaglutide?

In the head-to-head SURPASS-2 trial, tirzepatide produced greater A1C reduction and more weight loss than semaglutide 1 mg at all three doses, and obesity trials show a similar gap (about 22.5% vs 14.9%). On those metrics tirzepatide is more potent. But "better" isn't only about potency — semaglutide has a longer cardiovascular outcomes track record, more years of post-market safety data, and may be better covered by your insurance.

What's the difference between semaglutide and tirzepatide?

Semaglutide activates one hormone receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP), which is why it's called a dual agonist. Semaglutide is sold as Ozempic, Wegovy, and Rybelsus; tirzepatide is sold as Mounjaro and Zepbound. Both are once-weekly subcutaneous injections — tirzepatide just adds a second metabolic lever.

Which has fewer side effects, semaglutide or tirzepatide?

The profiles are similar — both are dominated by GI symptoms that peak during titration. In trials, tirzepatide tended to show slightly higher diarrhea and slightly lower nausea than semaglutide at comparable efficacy, but the differences are modest and individual tolerance varies more than the averages.

Can you switch from semaglutide to tirzepatide?

Yes, and there's no required washout period. Because the drugs are different molecules with no exact dose equivalence, your prescriber will restart you at tirzepatide's lowest dose (2.5 mg) and titrate up. Tracking symptoms and weight through the transition helps guide the new titration.

Is semaglutide or tirzepatide cheaper?

Brand list prices are broadly similar (roughly $1,000–1,350/month without insurance), and actual cost depends on your plan, the specific brand, and manufacturer savings programs. Check coverage for the specific brand your prescriber recommends.

Sources

1. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
4. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563

Whether you land on semaglutide or tirzepatide, both are once-weekly injections that reward a clean record — dose ladder, side effects, and weight over time. DoneDose makes it simple to log every injection, rotate sites, and bring real data to your next appointment, even across a switch between the two.